Expansion of our business is primarily driven by innovation. Our business model is to bring breakthrough innovation in generic API development and incremental improvement in the manufacturing process of existing products.
|API Polpharma is a holder of several process patents and the rate is targeted to minimum 10 applications per year|
|Time-to-market and First-to-File business oriented objectives have intensified creative work at all levels of API development|
|We respect legal principles governing intellectual property|
|We provide financial incentives for creation of our inventions|
|We actively pursue the protection of our intellectual property rights however we respect the freedom of culture movement and freedom of knowledge|
Respecting all third party intellectual rights, our own patent team is dedicated to designing and defending our processes.
We are experienced in designing new synthesis routes for producing APIs; our patent portfolio proves it.
Our prime assets are the knowledge and extensive expertise of our people.
We employ highly qualified specialists and constantly invest in their continuous education in areas such as:
A key to the success is a combination of in-house expertise and effective co-operation with scientific institutions.
Our company enjoys the benefit of the experience of specialized external laboratories and institutions both Polish and international, the majority of which are located in Germany, Italy, Sweden, Switzerland, The Netherlands, China and India.
The external cooperation is carried out in the following areas:
To implement wide regulations into our processes, we developed the following practices: